Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LMP 744

Next Previous
X
Search
Drug Profile

LMP 744

Alternative Names: LMP744; MJ-III-65; NSC 706744

Latest Information Update: 30 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Linus Oncology; National Cancer Institute (USA); Purdue University
  • Developer Gibson Oncology; National Cancer Institute (USA)
  • Class Antineoplastics; Dioxoles; Indenes; Isoquinolines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours
  • Preclinical Breast cancer; Glioblastoma

Most Recent Events

  • 24 Sep 2024 LMP 744 receives Orphan Drug status for Glioma in USA
  • 02 Jun 2023 Adverse events and PK data from phase I trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 12 Apr 2023 Preclinical trials in Breast cancer in USA (IV) (Gibson Oncology pipeline, April 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top